A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma

NCT02386111 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

17

Enrollment

INDUSTRY

Sponsor class

Stopped Portfolio re-prioritization

Conditions

Carcinoma, Renal Cell
Kidney Diseases
Kidney Neoplasms
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Neoplasms
Neoplasms by Histologic Type
Clear-cell Metastatic Renal Cell Carcinoma

Interventions

DRUG: Combination of varlilumab and sunitinib

Sponsor

Celldex Therapeutics